Back to search

Article

Determinants of passive antibody efficacy in SARS-CoV-2 infection

2022-03-22

Abstract excerpt

<h4>Summary</h4> <h4>Background</h4> A large number of studies have been carried out involving passive antibody administration for the treatment and prophylaxis of COVID-19 and have shown variable efficacy. However, the determinants of treatment effectiveness have not been identified. Here we aimed to aggregate all available data on randomised controlled trials of passive antibody treatment for COVID-19 to under...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
923b9653-3985-5a14-9d0f-6d03854370c2
DOI
10.1101/2022.03.21.22272672
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Determinants of passive antibody efficacy in SARS-CoV-2 infectionDOI 10.1101/2022.03.21.22272672
A statistical immune correlates of protection model for predicting efficacy from neutralizing antibody titers to establish immunobridging of monoclonal antibodies for prevention of COVID-19Semantic proximity
Clinical Virology and Effect of Vaccination and Monoclonal Antibodies against SARS-CoV-2 Omicron Sub Variant BF.7 (BA.5.2.1.7): A systematic reviewSemantic proximity
A single intramuscular injection of monoclonal antibody MAD0004J08 induces in healthy adults SARS-CoV-2 neutralising antibody titres exceeding those induced by infection and vaccinationSemantic proximity
EFFECTIVENESS OF CASIRIVIMAB-IMDEVIMAB AND SOTROVIMAB MONOCLONAL ANTIBODY TREATMENT AMONG HIGH-RISK PATIENTS WITH SARS-CoV-2 INFECTION: A REAL-WORLD EXPERIENCESemantic proximity
<i>In vivo</i> virological efficacy of monoclonal antibodies and direct antiviral agents against the SARS-CoV-2 BA.1 and BA.2 Omicron sublineagesSemantic proximity
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature reviewSemantic proximity
Antibody response to SARS-CoV-2 infection in humans: a systematic reviewSemantic proximity
Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19Semantic proximity
Long-term neutralizing antibody dynamics against SARS-CoV-2 in symptomatic and asymptomatic infections: a systematic review and meta-analysisSemantic proximity
RECOMBINANT HUMAN MONOCLONAL ANTIBODIES CASIRIVIMAB/IMDEVIMAB USE IN INHIBITION OF THE SARS-CoV-2 VIRUS INFECTIONSemantic proximity
Determinants of antibody responses to two doses of ChAdOx1 nCoV-19 or BNT162b2 and a subsequent booster dose of BNT162b2 or mRNA-1273: population-based cohort study (COVIDENCE UK)Semantic proximity
Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in Congolese individualsSemantic proximity
Select a neighboring publication to make it the new centre.